Background
==========

Toxoplasmosis is the most common parasitic infection in humans and probably the most common zoonosis in Poland \[[@b1-medscimonit-21-598],[@b2-medscimonit-21-598]\]. It is estimated that approximately 30% to 50% of the Polish population are infected with *T. gondii*, although over 80% of these are asymptomatic \[[@b3-medscimonit-21-598],[@b4-medscimonit-21-598]\].

Inflammation in the posterior eye segment occurs much later than the primary infection and is caused by a local reactivation resulting from rupture of tissue cysts that release dormant bradyzoites. This is due to weakened host immunity with the resulting inability to clear tachyzoites effectively, and is not due to an increased activity of the parasite \[[@b3-medscimonit-21-598],[@b5-medscimonit-21-598],[@b6-medscimonit-21-598]\].

Świtaj et al.*,* using a polymerase chain reaction (PCR) method, demonstrated genetic material of *T. gondii* in peripheral blood samples from nearly all patients with reactivation of ocular toxoplasmosis \[[@b7-medscimonit-21-598]\]. Similar findings were reported by Silveira et al. \[[@b8-medscimonit-21-598]\] and Park et al. \[[@b9-medscimonit-21-598]\]. There is a potential risk to the fetus as there have been reports of mother-to-child transmission during reactivation of maternal ocular toxoplasmosis in pregnancy \[[@b10-medscimonit-21-598],[@b11-medscimonit-21-598]\].

During pregnancy and postpartum period, the immune response is physiologically impaired and women are more susceptible to infections. Theoretically, this may predispose patients to reactivation of toxoplasmic retinochoroiditis \[[@b12-medscimonit-21-598]--[@b16-medscimonit-21-598]\]. Focal retinochoroiditis usually occurs many years after primary infection. Retinochoroiditis developing at the time of primary infection is very rare \[[@b17-medscimonit-21-598],[@b18-medscimonit-21-598]\].

The aim of this study was to present the management of toxoplasmic retinochoroiditis during pregnancy, postpartum period, or lactation.

Material and Methods
====================

A retrospective study was undertaken of the clinical records of 24 women, aged 15 to 39 years, during pregnancy, postpartum period, or lactation, who were treated at the Department of Zoonoses and Tropical Diseases and the Department of Ophthalmology, Medical University of Warsaw in the years 1994--2014. The diagnosis was based on the typical ophthalmoscopic picture, confirmed by serological testing for anti-*T. gondii* IgG and IgM, based on the enzyme-linked immunosorbent assay (ELISA) method. The choice of treatment was guided by the character and location of focal inflammation and the gestational age. Inflammation was considered to have been successfully treated when a scar was formed and the effusion resolved.

The study was approved by the Ethics Review Committee at the Medical University of Warsaw.

Results
=======

A total of 28 attacks of acute toxoplasmic retinochoroiditis were observed in 24 women. In 20 cases, these were recurrences and the other 8 patients reported their problem as the first attack, although an ophthalmologic examination in 7 patients revealed postinflammatory retinal scars, confirming previous reactivations. The 7 patients were probably not aware of their condition because the foci were clinically "silent", had peripheral location, or possibly were the result of childhood or even congenital infection. One patient (KSM, No. 16) actually presented with a first episode of toxoplasmic retinochoroiditis as she had no previous scars and a serologic test in the third trimester was negative. Judging from her serial serologic testing (i.e., the IgM and IgG results, and IgG avidity test) we estimate that seroconversion occurred approximately 7 months after delivery and 2 months before retinochoroiditis became evident.

Fifteen (15) of the patients were pregnant (4--32 weeks of pregnancy), 2 were in the postpartum period and 11 were lactating. In 2 pregnant patients, subsequent recurrences were observed in the postpartum period during lactation. One patient (RA, No. 1) had a history of acute toxoplasmic retinochoroiditis during her first pregnancy in 1991, followed by 3 reactivations: during her second pregnancy in 1994, when not pregnant in 1997, and again in 2002 during lactation after her third pregnancy. This is the most interesting case in our series and its rare nature prompted us to write this report. The retinal lesions in this patient are shown in [Figures 1](#f1-medscimonit-21-598){ref-type="fig"} and [2](#f2-medscimonit-21-598){ref-type="fig"}.

To date, 17 of the patients have had no reactivation toxoplasmic retinochoroiditis after completing their treatment, 9 had 1 reactivation, and another 4 had more than 1 relapse.

Clinical details of the patients are given in [Table 1](#t1-medscimonit-21-598){ref-type="table"}.

Pregnant patients
-----------------

All pregnant patients, except 1 who first presented when the active lesion had already settled, received topical treatment. Of those patients, 11 patients received spiramycin at doses of 3 million IU TID usually for 10 days and in 9 patients the inflammation was successfully treated. The 2 patients who did not respond to spiramycin were additionally prescribed Fansidar (pyrimethamine 25 mg/sulfadoxine 500 mg) 2 tablets/day for 2 days as a loading dose followed by 1 tablet/day for 19 days. Fansidar was also used in another patient who was at a risk of permanent damage of the macula. All women treated with Fansidar were \>12 weeks of pregnancy and were supplemented with 15 mg of folinic acid per a day.

Patient WJI (No. 10) was treated with spiramycin, Fansidar, azithromycin, and prednisone without folinic acid supplementation, because at the time of treatment she was not aware that she was pregnant. In 2 pregnant patients, topical treatment (steroidal/nonsteroidal anti-inflammatory eye drops) only was used because the patients were referred at the time when the peripherally situated active lesion was already settling. Prednisone was used depending on the effusion level in the vitreous body at a starting dose of 40 mg, which was then gradually tapered.

Non-pregnant patients
---------------------

Two episodes of retinochoroiditis reactivation were observed in the postpartum period and 11 episodes occurred during lactation. In all cases topical treatment (steroidal/nonsteroidal anti-inflammatory eye drops) was given and in 12 cases the patients were treated with a multidrug regimen including Fansidar, spiramycin (at a doses of 3 million IU TID for 10 days), and azithromycin (at a dose of 0.5g/day for 6 days). Prednisone was used depending on the effusion level in the vitreous body at a starting dose of 40 mg, which was then gradually tapered.

Fansidar was used after suppressing lactation. The patients took 1 tablet BID for 2 days, followed by 1 tablet QD for 19 days and 1 tablet twice a week for 6 months. The aim was to achieve permanent remission of recurrent retinochoroiditis. Platelet depletion as an adverse effect of anti-folinic drugs (Fansidar) was not observed.

The offspring of both pregnant and non-pregnant patients were not included in the present study.

Discussion
==========

In pregnancy, the immune responses are physiologically impaired to prevent the rejection of the fetus and this weakening of the immune system may continue in the postpartum period and during lactation. Reactivation of inflammation associated with infectious disease is not infrequent and higher rates of ocular toxoplasmosis recurrence may be expected \[[@b5-medscimonit-21-598],[@b12-medscimonit-21-598]\]. Our literature search yielded only a few reports of toxoplasmic retinochoroiditis in pregnant patients \[[@b12-medscimonit-21-598]--[@b14-medscimonit-21-598],[@b18-medscimonit-21-598]--[@b20-medscimonit-21-598]\].

It is generally acknowledged that primary *T. gondii* infection in pregnancy carries a risk of transplacental infection with potentially serious neurological and ocular complications in the newborn. The risk increases with the gestational age, with the highest rate in the third trimester and the lowest rate in the first trimester, the average transmission rate being 30% \[[@b14-medscimonit-21-598],[@b17-medscimonit-21-598],[@b18-medscimonit-21-598]\]. A review of the literature covering the last 30 years revealed no evidence of a reduction in transplacental transmission rates of *T. gondii* resulting from the treatment of active toxoplasmosis in pregnancy, although decreased severity of congenital toxoplasmosis symptoms has been observed \[[@b21-medscimonit-21-598],[@b22-medscimonit-21-598]\]. Thus, treatment does not have any effect on the potential disease in the offspring, but it may be effective in the mother. However, potential adverse effects in the fetus are a considerable concern \[[@b21-medscimonit-21-598]\]. Generally, spiramycin is a first-choice drug in toxoplasmosis in pregnancy and it can prevent transplacental transmission of *T. gondii*.

Importantly, toxoplasmic retinochoroiditis is a self-limiting condition and may resolve without treatment within 6 to 8 weeks \[[@b23-medscimonit-21-598],[@b24-medscimonit-21-598]\]. In his report, Holland found spontaneous resolution of active inflammation with a resulting scar in patients with peripheral, not sight-threatening, locations of the active lesion \[[@b17-medscimonit-21-598]\]. According to Rothova et al.*,* in cases of peripheral lesions or when there are contraindications for treatment (e.g., pregnancy), ocular toxoplasmosis does not require treatment \[[@b24-medscimonit-21-598]\].

In the reported series of female patients we did not find any massive inflammation in the vitreous and retina or related complications as described by Kump et al. \[[@b12-medscimonit-21-598]\]. The course of retinochoroiditis did not differ from that in non-pregnant women or in men.

The question of whether to treat ocular toxoplasmosis has been disputed for many years because the therapy is expensive and may be associated with adverse events, and when the lesions are peripheral and not sight-threatening it may offer no benefits to the patients.

Transplacental transmission of *T. gondii* is potentially possible in mothers with focal retinitis that occurred after remote primary infection. Treatment that is safe for the fetus should be instituted in each case to decrease the likelihood of maternofetal transmission \[[@b7-medscimonit-21-598]--[@b11-medscimonit-21-598],[@b18-medscimonit-21-598]\].

In pregnancy the management of toxoplasmic retinochoroiditis should be individualized. It is necessary to consider a possible threat to sight in the mother, protection of the fetus against potential risk of transplacental transmission, and potential adverse effects of the treatment to the fetus, which is very susceptible to the effects of medication during organogenesis and then less so in the second and third trimesters.

Nowadays, specific treatments for *T. gondii* infection include products belonging to the classes of macrolide antibiotics, sulfonamides, and pyrimethamine \[[@b1-medscimonit-21-598],[@b25-medscimonit-21-598]--[@b27-medscimonit-21-598]\].

Spiramycin was prescribed in pregnant women treated at our institutions as a first-choice drug because it is effective against *T. gondii*, and although it crosses the placental barrier in small amounts, it is not teratogenic. Spiramycin was given until focal retinochoroiditis resolved.

Treatment with the anti-folinic product (pyrimethamine 25 mg/sulfadoxine 500 mg), which is considered to be the most effective, was prescribed to pregnant women in the case of vision-threatening lesions or when there was no response to spiramycin, and only in late pregnancy. During lactation, the patients were advised to discontinue breast-feeding and then they were treated with anti-folinic products.

Fansidar, a very potent drug, is a combination of pyrimethamine and sulfadoxine, which suppress the synthesis of folic acid in protozoa, thus blocking cell division. Fansidar crosses the placental barrier and in animal studies (rat) it was embryotoxic, but no teratogenic effects have been reported in humans \[[@b28-medscimonit-21-598]--[@b30-medscimonit-21-598]\]. However, it produces folic acid deficiency in patients, with subsequent bone marrow suppression. Pregnant women treated with Fansidar were advised to take folinic acid, which is converted in the body to active folate, to prevent folate deficiency \[[@b1-medscimonit-21-598],[@b27-medscimonit-21-598]\].

When there is no response to spiramycin, it is usually substituted with azithromycin, which has a much greater capacity to cross biological barriers, with effective intraocular penetration when the inflammation is settling. Azithromycin crosses the placental barrier easily, which is why its use is avoided it during pregnancy.

WJI (No. 10) was not aware of her pregnancy when treatment was initiated with Fansidar and spiramycin (swiched after 10 days for azitromycin for 6 days), followed by Fansidar alone, which she discontinued at 17 Hbd. She did not recive any folinic acid supplementation. However, she gave birth to a baby who had no signs of folate deficiency and whose further growth and development were normal.

Although the patients' offspring were not included in this study, obstetricians and perinatologists were informed about maternal toxoplasma reactivation and the potential risk for placental transmission. To the best of our knowledge, none of newborns had any clinical signs of congenital toxoplasmosis, which was additionally confirmed by serologic testing.

Conclusions
===========

The importance of secondary prophylaxis should be borne in mind, and Fansidar (pyrimethamine/sulfadoxine) may be administered at low doses for 6 months after recurrent toxoplasmic retinochoroiditis has resolved. Ocular toxoplasmosis may be in remission for many months or even years and then become reactivated, which must be always considered, especially in women of childbearing age \[[@b31-medscimonit-21-598]\].

**Source of support:** Departmental sources

![Fourth reported reactivation of toxoplasmic retinochoroiditis in patients RA, No. 9.](medscimonit-21-598-g001){#f1-medscimonit-21-598}

![This same eye 1 month later after the treatment -- formed retinal scar.](medscimonit-21-598-g002){#f2-medscimonit-21-598}

###### 

Clinical details of the patients.

  Patient No.   Patient initials   Age   Date of first visit   Pregnancy (months)   Number of pregnancy   Lactation (months)   Treatment       Number of the retinal scars   Reactivation before pregnancy   Reactivation after pregnancy   Comments
  ------------- ------------------ ----- --------------------- -------------------- --------------------- -------------------- --------------- ----------------------------- ------------------------------- ------------------------------ ---------------------------------------------------------
  1             RA 2x              27    06-1994               18                   2                     0                    0               2                             1                               2                              Previous reactivation in first pregnancy in 1991
  2             GM                 15    08-1995               19                   1                     0                    T               2                             0                               2                              0
  3             AMA                20    03-1997               11                   1                     0                    T               1                             0                               3                              0
  4             NB                 25    11-1997               0                    1                     6                    S+F+A +P+E, T   3                             1                               2                              0
  5             GA                 28    05-1999               21                   2                     0                    S+F+FA          4                             1                               2                              Risk of damage to the macula
  6             FJE                24    10-2000               15                   1                     0                    S+F+FA          3                             2                               0                              Risk of damage to the papillo-macular area
  7             SA                 22    10-2001               0                    1                     3                    S+F+A T         4                             0                               0                              
  8             KM                 23    12-2001               24                   1                     0                    S+F+FA          1                             1                               0                              Risk of damage to the macula
  9             RA 3x              35    01-2002               0                    3                     6                    S+F+A, T        4                             3                               0                              Another reactivation in Patient No 1
  10            WJI                22    10-2002               4                    1                     0                    S+F+A+P,        3                             2                               1                              Not aware of her pregnancy. Stopped treatment at 17 Hbd
  11            JZ1x               29    01-2004               32                   1                     0                    S               1                             0                               1                              0
  12            MSM                24    07-2004               4                    1                     0                    S               2                             0                               0                              0
  13            KJ                 22    10-2004               15                   1                     0                    S               3                             1                               0                              0
  14            JZ2x               30    06-2005               0                    1                     12                   S+F+A+P, T      1                             1                               0                              Another reactivation in Patient No 1
  15            ZK                 30    03-2006               0                    1                     0,5                  S+R+A+P, T      1                             0                               0                              0
  16            KSM                39    08-2006               0                    1                     9                    S+F+A+P, T      0                             0                               0                              Seroconversion 8 months earlier
  17            RE                 25    05-2008               0                    2                     9                    S+F+A+P, T      4                             5                               0                              0
  18            ChSK               28    05-2008               25                   2                     0                    S+P             6                             2                               1                              0
  19            BCM                33    08-2008               11                   1                     0                    S+P             4                             1                               0                              0
  20            DW                 24    12-2009               0                    1                     6                    S+F+A+P, T      2                             0                               0                              0
  21            AP 1x              19    12-2009               12                   2                     0                    S               2                             1                               1                              0
  22            BD                 29    04-2009               0                    2                     6                    S+F+A+P, T      3                             1                               0                              0
  23            TD                 38    07-2010               0                    1                     6                    S+F+A+P, T      3                             1                               0                              0
  24            AP 2x              20    07-2010               0                    2                     1                    S+F+A+P, T      3                             2                               0                              Another reactivation in Patient No 21
  25            GP                 22    12-2011               0                    1                     2                    S+P, T          6                             2                               1                              0
  26            PBK                34    01-2012               0                    1                     2                    S+F+A+P, T      1                             1                               1                              0
  27            GBM                25    07-2013               12                   1                     0                    S+P             4                             1                               0                              0
  28            MK                 30    02-2014               28                   1                     0                    S+P             3                             2                               0                              0

S -- spiramycin; F -- fansidar (pyrimethamine+sulfadoxine); A -- azitromycin; P -- prednisone; FA -- folinic acid; T -- topically.
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